EcoDrugPlus

Cholinergic Receptor, Muscarinic 3a

Ensembl ID : ENSDARG00000071091
Gene Symbol: CHRM3A
8 Enzyme and pathways 5 Cross references
188 Possible Orthologues:

Cholinergic Receptor, Muscarinic 3b

Ensembl ID : ENSDARG00000071298
Gene Symbol: CHRM3B
5 Cross references
187 Possible Orthologues:

Cholinergic Receptor, Muscarinic 4a

Ensembl ID : ENSDARG00000069254
Gene Symbol: CHRM4A
8 Enzyme and pathways 5 Cross references
186 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5a

Ensembl ID : ENSDARG00000099928
Gene Symbol: CHRM5A
8 Enzyme and pathways 5 Cross references
195 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5b

Ensembl ID : ENSDARG00000069598
Gene Symbol: CHRM5B
5 Cross references
190 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 3

Ensembl ID : ENSDARG00000100991
Gene Symbol: CHRNA3
9 Enzyme and pathways 5 Cross references
202 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 4a

Ensembl ID : ENSDARG00000087071
Gene Symbol: CHRNA4A
3 Cross references
138 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 4b

Ensembl ID : ENSDARG00000070724
Gene Symbol: CHRNA4B
9 Enzyme and pathways 5 Cross references
192 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 7 (Neuronal)

Ensembl ID : ENSDARG00000101702
Gene Symbol: CHRNA7
5 Cross references
208 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Beta 2

Ensembl ID : ENSDARG00000017790
Gene Symbol: CHRNB2
9 Enzyme and pathways 5 Cross references
198 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Beta 4 (Neuronal)

Ensembl ID : ENSDARG00000101677
Gene Symbol: CHRNB4
12 Enzyme and pathways 5 Cross references
194 Possible Orthologues:

Coagulation Factor Ii (Thrombin) Receptor

Ensembl ID : ENSDARG00000060012
Gene Symbol: F2R
10 Enzyme and pathways 5 Cross references
211 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).